Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll ...

Xenon Pharmaceuticals (XENE) said late Thursday it submitted a new drug application for azetukalner in focal seizures to the US Food and Drug Administration. The submission is bas ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, ...

Most newly diagnosed patients with focal epilepsy continued to have seizures for a year or more after starting antiseizure medications (ASMs), results from the latest Human Epilepsy Project (HEP) ...

Focal epilepsy, characterised by seizures originating within a circumscribed region of the cerebral cortex, affects millions worldwide and often proves refractory to initial pharmacotherapy. The ...

Share on Pinterest A new drug reduced seizures in subjects with treatment resistant epilepsy in a recent clinical trial. The Good Brigade/Getty Images Researchers say a new medication may potentially ...

Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.

Xenon announces azetukalner NDA submission to US FDA for focal seizures, provides update on psychiatry clinical program: Vancouver, British Columbia Saturday, September 19, 2026, ...